Research ExplorerPublicationsPrognoses of MDS subtypes RARS, RCMD and RCMD-RS are compara...

Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course.

Standard

Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course. / Bacher, Ulrike; Kern, Wolfgang; Alpermann, Tamara; Schnittger, Susanne; Haferlach, Claudia; Haferlach, Torsten.

In: LEUKEMIA RES, Vol. 36, No. 7, 7, 2012, p. 826-831.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Bacher, U, Kern, W, Alpermann, T, Schnittger, S, Haferlach, C & Haferlach, T 2012, 'Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course.', LEUKEMIA RES, vol. 36, no. 7, 7, pp. 826-831. <http://www.ncbi.nlm.nih.gov/pubmed/22554895?dopt=Citation>

APA

Bacher, U., Kern, W., Alpermann, T., Schnittger, S., Haferlach, C., & Haferlach, T. (2012). Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course. LEUKEMIA RES, 36(7), 826-831. [7]. http://www.ncbi.nlm.nih.gov/pubmed/22554895?dopt=Citation

Vancouver

Bacher U, Kern W, Alpermann T, Schnittger S, Haferlach C, Haferlach T. Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course. LEUKEMIA RES. 2012;36(7):826-831. 7.

Bibtex

@article{ede898808e7d4d629d07cff44c5ec56e,
title = "Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course.",
abstract = "In 2008, the WHO combined the former categories RCMD (refractory cytopenia with multilineage dysplasia) and RCMD-RS (ring sideroblasts ? 15%). We studied the clinical impact and genetic background of RARS, RCMD, and RCMD-RS in 1082 patients. Good karyotypes (IPSS) were similarly frequent in RARS, RCMD, and RCMD-RS. 2-year overall survival (OS) rates were similar in RARS, RCMD, and RCMD-RS (85.9%/89.0%/91.7%; n.s.). The 2-year OS rate was better in good than intermediate or poor karyotypes (p<0.001). These results support to combine RCMD and RCMD-RS as performed by WHO and emphasize the prognostic power of cytogenetic criteria for these MDS subtypes.",
keywords = "Adult, Humans, Male, Aged, Female, Middle Aged, Aged, 80 and over, Young Adult, Cohort Studies, Prognosis, Survival Analysis, Anemia, Refractory/*diagnosis/epidemiology/genetics/mortality, Anemia, Sideroblastic/*diagnosis/epidemiology/genetics/mortality, Cytogenetics/methods, Myelodysplastic Syndromes/*classification/*diagnosis/genetics/mortality, Adult, Humans, Male, Aged, Female, Middle Aged, Aged, 80 and over, Young Adult, Cohort Studies, Prognosis, Survival Analysis, Anemia, Refractory/*diagnosis/epidemiology/genetics/mortality, Anemia, Sideroblastic/*diagnosis/epidemiology/genetics/mortality, Cytogenetics/methods, Myelodysplastic Syndromes/*classification/*diagnosis/genetics/mortality",
author = "Ulrike Bacher and Wolfgang Kern and Tamara Alpermann and Susanne Schnittger and Claudia Haferlach and Torsten Haferlach",
year = "2012",
language = "English",
volume = "36",
pages = "826--831",
journal = "LEUKEMIA RES",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "7",

}

RIS

TY - JOUR

T1 - Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course.

AU - Bacher, Ulrike

AU - Kern, Wolfgang

AU - Alpermann, Tamara

AU - Schnittger, Susanne

AU - Haferlach, Claudia

AU - Haferlach, Torsten

PY - 2012

Y1 - 2012

N2 - In 2008, the WHO combined the former categories RCMD (refractory cytopenia with multilineage dysplasia) and RCMD-RS (ring sideroblasts ? 15%). We studied the clinical impact and genetic background of RARS, RCMD, and RCMD-RS in 1082 patients. Good karyotypes (IPSS) were similarly frequent in RARS, RCMD, and RCMD-RS. 2-year overall survival (OS) rates were similar in RARS, RCMD, and RCMD-RS (85.9%/89.0%/91.7%; n.s.). The 2-year OS rate was better in good than intermediate or poor karyotypes (p<0.001). These results support to combine RCMD and RCMD-RS as performed by WHO and emphasize the prognostic power of cytogenetic criteria for these MDS subtypes.

AB - In 2008, the WHO combined the former categories RCMD (refractory cytopenia with multilineage dysplasia) and RCMD-RS (ring sideroblasts ? 15%). We studied the clinical impact and genetic background of RARS, RCMD, and RCMD-RS in 1082 patients. Good karyotypes (IPSS) were similarly frequent in RARS, RCMD, and RCMD-RS. 2-year overall survival (OS) rates were similar in RARS, RCMD, and RCMD-RS (85.9%/89.0%/91.7%; n.s.). The 2-year OS rate was better in good than intermediate or poor karyotypes (p<0.001). These results support to combine RCMD and RCMD-RS as performed by WHO and emphasize the prognostic power of cytogenetic criteria for these MDS subtypes.

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Aged, 80 and over

KW - Young Adult

KW - Cohort Studies

KW - Prognosis

KW - Survival Analysis

KW - Anemia, Refractory/diagnosis/epidemiology/genetics/mortality

KW - Anemia, Sideroblastic/diagnosis/epidemiology/genetics/mortality

KW - Cytogenetics/methods

KW - Myelodysplastic Syndromes/classification/diagnosis/genetics/mortality

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Aged, 80 and over

KW - Young Adult

KW - Cohort Studies

KW - Prognosis

KW - Survival Analysis

KW - Anemia, Refractory/diagnosis/epidemiology/genetics/mortality

KW - Anemia, Sideroblastic/diagnosis/epidemiology/genetics/mortality

KW - Cytogenetics/methods

KW - Myelodysplastic Syndromes/classification/diagnosis/genetics/mortality

M3 - SCORING: Journal article

VL - 36

SP - 826

EP - 831

JO - LEUKEMIA RES

JF - LEUKEMIA RES

SN - 0145-2126

IS - 7

M1 - 7

ER -